These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 10066944)
1. [Phase III trials in oncology]. Imadalou K; Cvitkovic E Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944 [TBL] [Abstract][Full Text] [Related]
2. Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ; J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802 [TBL] [Abstract][Full Text] [Related]
3. On the efficiency of targeted clinical trials. Maitournam A; Simon R Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403 [TBL] [Abstract][Full Text] [Related]
4. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Jenkins M; Stone A; Jennison C Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327 [TBL] [Abstract][Full Text] [Related]
5. A strategic framework for novel drug development in multiple myeloma. Anderson KC; Hannah AL; Pazdur R; Farrell AT Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022 [No Abstract] [Full Text] [Related]
6. Improving the design of phase II trials of cytostatic anticancer agents. Stone A; Wheeler C; Barge A Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736 [TBL] [Abstract][Full Text] [Related]
7. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs. Vaucher P Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773 [TBL] [Abstract][Full Text] [Related]
8. Design of randomized controlled trials. Stanley K Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574 [No Abstract] [Full Text] [Related]
10. Optimising the design of phase II oncology trials: the importance of randomisation. Ratain MJ; Sargent DJ Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773 [TBL] [Abstract][Full Text] [Related]
11. [Principle and practice of clinical phase III studies]. Morant R Onkologie; 2008; 31 Suppl 2():53-7. PubMed ID: 18487870 [TBL] [Abstract][Full Text] [Related]
12. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. Beitz J; Gnecco C; Justice R J Natl Cancer Inst Monogr; 1996; (20):7-9. PubMed ID: 8750460 [TBL] [Abstract][Full Text] [Related]
14. Optimizing randomized phase II trials assessing tumor progression. Stone A; Wheeler C; Carroll K; Barge A Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129 [TBL] [Abstract][Full Text] [Related]
15. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design. Taylor JM; Braun TM; Li Z Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208 [TBL] [Abstract][Full Text] [Related]
16. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Suman VJ; Dueck A; Sargent DJ Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764 [No Abstract] [Full Text] [Related]
17. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Amit O; Mannino F; Stone AM; Bushnell W; Denne J; Helterbrand J; Burger HU Eur J Cancer; 2011 Aug; 47(12):1772-8. PubMed ID: 21429737 [TBL] [Abstract][Full Text] [Related]
18. From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside. Sakamoto J; Morita S Nagoya J Med Sci; 2007 Jan; 69(1-2):9-16. PubMed ID: 17378175 [TBL] [Abstract][Full Text] [Related]